

Formpipe - Softer ACV – Promising Initiatives

Redeye keeps its Base Case despite cutting its 2024-2025 EBIT forecasts following a Q3 report with somewhat soft numbers. However, the Public segment is taking steps in the right direction, and we are encouraged by the new growth initiatives in the Private and Public segments.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Formpipe - Softer ACV – Promising Initiatives